Payment overview · 2025
General Payments
$1,254.97
22 reported records · 14 companies
Healthcare provider profile · identity verified
Michael Allen Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · COLUMBIA, MO · NPI 1760500987
Verified facts
What the public records show
CMS Open Payments records show Michael Allen Brown, M.D. received $1,254.97 in general payments during 2025 across 22 reported records.
Inari Medical, Inc. accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 447 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Adempas by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $537.60 | 42.8% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $120.59 | 9.6% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $96.29 | 7.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $92.09 | 7.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$88.87 | 7.1% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $75.67 | 6.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.23 | 4.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $54.76 | 4.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.65 | 3.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.15 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.44 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.32 | 1.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.19 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $774.01 | 20 |
| Travel and Lodging | $480.96 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $537.60 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $537.60 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $96.29 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $92.09 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $88.87 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $75.67 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $56.23 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.65 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $36.56 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 447 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
447 | 89 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
131 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 815 | 212 |
| Clopidogrel | Clopidogrel Bisulfate | 711 | 177 |
| Carvedilol | Carvedilol | 523 | 147 |
| Eliquis | Apixaban | 447 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 446 | 105 |
| Cilostazol | Cilostazol | 384 | 90 |
| Furosemide | Furosemide | 311 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 79 |
| Lisinopril | Lisinopril | 276 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 264 | 71 |
| Losartan Potassium | Losartan Potassium | 229 | 65 |
| Warfarin Sodium | Warfarin Sodium | 173 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 34 |
| Entresto | Sacubitril/Valsartan | 131 | 26 |
| Repatha Sureclick | Evolocumab | 120 | 33 |
| Potassium Chloride | Potassium Chloride | 110 | 26 |
| Xarelto | Rivaroxaban | 107 | 24 |
| Spironolactone | Spironolactone | 105 | 29 |
| Ezetimibe | Ezetimibe | 96 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 56 | 14 |
| Sotalol | Sotalol Hcl | 56 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 14 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Praluent Pen | Alirocumab | 48 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 44 | suppressed |
| Pentoxifylline | Pentoxifylline | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 12 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Simvastatin | Simvastatin | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Adempas | Riociguat | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Camzyos | Mavacamten | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,254.97 · 22 records | Inari Medical, Inc. | AURYON LASER SYSTEM 100-120 VAC, AVVIGO Guidance System, CAMZYOS, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, LEQVIO, Repatha, SYMPLICITY G3, VERQUVO, Vest Therapy Und, WAINUA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error